Comparative Pharmacology
Head-to-head clinical analysis: ACCUNEB versus VOLMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUNEB versus VOLMAX.
ACCUNEB vs VOLMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP, leading to bronchodilation.
Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.
Adults: 4-8 mg orally every 12 hours (sustained-release); maximum 16 mg every 12 hours.
None Documented
None Documented
2-5 hours (procainamide); 6-8 hours (N-acetylprocainamide); prolonged in renal impairment (up to 20 hours)
Terminal elimination half-life: 4-6 hours. Clinical context: requires twice-daily dosing in asthma.
Renal: ~70% as unchanged drug and active metabolite (N-acetylprocainamide) within 24 hours; biliary/fecal: minimal (<5%)
Renal: 60-70% (unchanged and metabolites); fecal: 15-25%; biliary: <5%.
Category C
Category C
Beta-2 Agonist
Beta-2 Agonist